Estrella Immunopharma Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
ESLA$0.75+45.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Balance Sheets
| As of September 30, 2024 · As of June 30, 2024 | |||
|---|---|---|---|
| (Unaudited) | |||
| Assets | |||
| Current assets: | |||
| Cash and cash equivalent | $1,797,503 | $4,165,428 | |
| Prepaid expenses and other receivable | 437,642 | 288,761 | |
| Total current assets | 2,235,145 | 4,454,189 | |
| Other Assets | |||
| Prepaid expenses - related party, non-current | 1,500,000 | - | |
| Total Assets | $3,735,145 | $4,454,189 | |
| Liabilities, Preferred Stock and Stockholders’ Equity | |||
| Current liabilities: | |||
| Accounts payable - related party | $5,000 | $ | - |
| Other payables and accrued liabilities | 188,981 | 131,823 | |
| Accrued liability - related party | 2,750,000 | 4,000 | |
| Franchise tax payables | 4,134 | 4,134 | |
| Income tax payables | 40,744 | 40,744 | |
| Total current liabilities | 2,988,859 | 180,701 | |
| Total Liabilities | 2,988,859 | 180,701 | |
| Commitments and Contingencies (Note 8) | |||
| Preferred Stock* | |||
| Series A Preferred Stock, $0.0001 par value, 15,000,000 shares authorized; 0 shares issued and outstanding as of September 30, 2024 and June 30, 2024, respectively; | - | - | |
| Series AA Preferred Stock, $0.0001 par value, 105,000,000 shares authorized; 0 shares issued and outstanding as of September 30, 2024 and June 30, 2024, respectively; | - | - | |
| Stockholders’ Equity: | |||
| Common stock, $0.0001 par value; 250,000,000 shares authorized; 36,610,870 shares issued as of September 30, 2024 and June 30, 2024 | 3,661 | 3,661 | |
| Additional paid-in capital | 24,124,543 | 24,124,543 | |
| Accumulated deficit | (22,877,013) | (19,500,276) | |
| Treasury stock, at cost 431,723 and 321,794 shares as of September 30, 2024 and June 30, 2024, respectively | (504,905) | (354,440) | |
| Total Stockholders’ Equity | 746,286 | 4,273,488 | |
| Total Liabilities, Preferred Stock and Stockholders’ Equity | $3,735,145 | $4,454,189 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.